Recruitment and activation of type 3 innate lymphoid cells promote antitumor immune responses.
Animals
CD4-Positive T-Lymphocytes
/ immunology
CD8-Positive T-Lymphocytes
/ immunology
Cell Line, Tumor
Cytokines
/ immunology
Female
Humans
Immune Checkpoint Inhibitors
/ immunology
Immunity, Innate
/ immunology
Lymphocytes
/ immunology
Mice
Mice, Inbred BALB C
Mice, Inbred C57BL
Neoplasms
/ immunology
Journal
Nature immunology
ISSN: 1529-2916
Titre abrégé: Nat Immunol
Pays: United States
ID NLM: 100941354
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
received:
01
04
2021
accepted:
13
12
2021
pubmed:
2
2
2022
medline:
19
2
2022
entrez:
1
2
2022
Statut:
ppublish
Résumé
Tumors poorly infiltrated by T cells are more resistant to immunogenic chemotherapies and checkpoint inhibition than highly infiltrated tumors. Using murine models, we found that CCR6
Identifiants
pubmed: 35102345
doi: 10.1038/s41590-021-01120-y
pii: 10.1038/s41590-021-01120-y
doi:
Substances chimiques
Cytokines
0
Immune Checkpoint Inhibitors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
262-274Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature America, Inc.
Références
Galon, J. et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313, 1960–1964 (2006).
pubmed: 17008531
doi: 10.1126/science.1129139
Larkin, J. et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 381, 1535–1546 (2019).
pubmed: 31562797
doi: 10.1056/NEJMoa1910836
Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568–571 (2014).
pubmed: 25428505
pmcid: 4246418
doi: 10.1038/nature13954
Matsutani, S. et al. Significance of tumor-infiltrating lymphocytes before and after neoadjuvant therapy for rectal cancer. Cancer Sci. 109, 966–979 (2018).
pubmed: 29464828
pmcid: 5891199
doi: 10.1111/cas.13542
Irshad, S. et al. RORγt
pubmed: 28082403
doi: 10.1158/0008-5472.CAN-16-0598
Kirchberger, S. et al. Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model. J. Exp. Med. 210, 917–931 (2013).
pubmed: 23589566
pmcid: 3646494
doi: 10.1084/jem.20122308
Eisenring, M., vom Berg, J., Kristiansen, G., Saller, E. & Becher, B. IL-12 initiates tumor rejection via lymphoid tissue-inducer cells bearing the natural cytotoxicity receptor NKp46. Nat. Immunol. 11, 1030–1038 (2010).
pubmed: 20935648
doi: 10.1038/ni.1947
Nussbaum, K. et al. Tissue microenvironment dictates the fate and tumor-suppressive function of type 3 ILCs. J. Exp. Med. 214, 2331–2347 (2017).
pubmed: 28698286
pmcid: 5551572
doi: 10.1084/jem.20162031
Dieu-Nosjean, M.-C. et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J. Clin. Oncol. 26, 4410–4417 (2008).
pubmed: 18802153
doi: 10.1200/JCO.2007.15.0284
Ben-Sasson, S. Z. et al. IL-1 enhances expansion, effector function, tissue localization, and memory response of antigen-specific CD8 T cells. J. Exp. Med. 210, 491–502 (2013).
pubmed: 23460726
pmcid: 3600912
doi: 10.1084/jem.20122006
Voronov, E. & Apte, R. N. IL-1 in colon inflammation, colon carcinogenesis and invasiveness of colon cancer. Cancer Microenviron. 8, 187–200 (2015).
pubmed: 26686225
pmcid: 4715003
doi: 10.1007/s12307-015-0177-7
Mortha, A. et al. Microbiota-dependent crosstalk between macrophages and ILC3 promotes intestinal homeostasis. Science 343, 1249288 (2014).
pubmed: 24625929
pmcid: 4291125
doi: 10.1126/science.1249288
Zhou, L. et al. Innate lymphoid cells support regulatory T cells in the intestine through interleukin-2. Nature 568, 405–409 (2019).
pubmed: 30944470
pmcid: 6481643
doi: 10.1038/s41586-019-1082-x
Hirota, K. et al. Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal model. J. Exp. Med. 204, 2803–2812 (2007).
pubmed: 18025126
pmcid: 2118525
doi: 10.1084/jem.20071397
Kleinewietfeld, M. et al. CCR6 expression defines regulatory effector/memory-like cells within the CD25
pubmed: 15613550
doi: 10.1182/blood-2004-07-2505
Ito, T., Carson, W. F., Cavassani, K. A., Connett, J. M. & Kunkel, S. L. CCR6 as a mediator of immunity in the lung and gut. Exp. Cell. Res. 317, 613–619 (2011).
pubmed: 21376174
pmcid: 3063449
doi: 10.1016/j.yexcr.2010.12.018
Li, Z. et al. Epidermal Notch1 recruits RORγ
pubmed: 27099134
pmcid: 4844683
doi: 10.1038/ncomms11394
Gandhi, L. et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N. Engl. J. Med. 378, 2078–2092 (2018).
pubmed: 29658856
doi: 10.1056/NEJMoa1801005
Withers, D. R. et al. Transient inhibition of ROR-γt therapeutically limits intestinal inflammation by reducing TH17 cells and preserving group 3 innate lymphoid cells. Nat. Med. 22, 319–323 (2016).
pubmed: 26878233
pmcid: 4948756
doi: 10.1038/nm.4046
Huh, J. R. et al. Digoxin and its derivatives suppress TH17 cell differentiation by antagonizing RORγt activity. Nature 472, 486–490 (2011).
pubmed: 21441909
pmcid: 3172133
doi: 10.1038/nature09978
Xiao, S. et al. Small-molecule RORγt antagonists inhibit T helper 17 cell transcriptional network by divergent mechanisms. Immunity 40, 477–489 (2014).
pubmed: 24745332
pmcid: 4066874
doi: 10.1016/j.immuni.2014.04.004
Mebius, R. E., Rennert, P. & Weissman, I. L. Developing lymph nodes collect CD4
pubmed: 9354470
doi: 10.1016/S1074-7613(00)80371-4
Carrega, P. et al. NCR
pubmed: 26395069
doi: 10.1038/ncomms9280
Maurice, N. J., McElrath, M. J., Andersen-Nissen, E., Frahm, N. & Prlic, M. CXCR3 enables recruitment and site-specific bystander activation of memory CD8
pubmed: 31676770
pmcid: 6825240
doi: 10.1038/s41467-019-12980-2
Takatori, H. et al. Lymphoid tissue inducer-like cells are an innate source of IL-17 and IL-22. J. Exp. Med. 206, 35–41 (2009).
pubmed: 19114665
pmcid: 2626689
doi: 10.1084/jem.20072713
Godec, J. et al. Compendium of immune signatures identifies conserved and species-specific biology in response to inflammation. Immunity 44, 194–206 (2016).
pubmed: 26795250
pmcid: 5330663
doi: 10.1016/j.immuni.2015.12.006
Paget, C. et al. CD3bright signals on γδ T cells identify IL-17A-producing Vγ6Vδ1
pubmed: 25385067
doi: 10.1038/icb.2014.94
Koh, J. et al. IL23-producing human lung cancer cells promote tumor growth via conversion of innate lymphoid cell 1 (ILC1) into ILC3. Clin. Cancer Res. 25, 4026–4037 (2019).
pubmed: 30979738
doi: 10.1158/1078-0432.CCR-18-3458
Munneke, J. M. et al. Activated innate lymphoid cells are associated with a reduced susceptibility to graft-versus-host disease. Blood 124, 812–821 (2014).
pubmed: 24855210
doi: 10.1182/blood-2013-11-536888
Trabanelli, S. et al. CD127
pubmed: 25710455
pmcid: 4486236
doi: 10.3324/haematol.2014.119602
Kuo, P. T. et al. The role of CXCR3 and its chemokine ligands in skin disease and cancer. Front. Med. 5, 271 (2018).
doi: 10.3389/fmed.2018.00271
Sato, Y. et al. CXCL10 expression status is prognostic in patients with advanced thoracic esophageal squamous cell carcinoma. Ann. Surg. Oncol. 23, 936–942 (2016).
pubmed: 26464192
doi: 10.1245/s10434-015-4909-1
Sonnenberg, G. F., Monticelli, L. A., Elloso, M. M., Fouser, L. A. & Artis, D. CD4
pubmed: 21194981
doi: 10.1016/j.immuni.2010.12.009
Ranasinghe, R. & Eri, R. Modulation of the CCR6-CCL20 axis: a potential therapeutic target in inflammation and cancer. Medicina (Kaunas) 54, 88 (2018).
doi: 10.3390/medicina54050088
Wang, D. et al. Colorectal cancer cell-derived CCL20 recruits regulatory T cells to promote chemoresistance via FOXO1/CEBPB/NF-κB signaling. J. Immunother. Cancer 7, 215 (2019).
pubmed: 31395078
pmcid: 6688336
doi: 10.1186/s40425-019-0701-2
Spranger, S., Dai, D., Horton, B. & Gajewski, T. F. Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy. Cancer Cell 31, 711–723 (2017).
pubmed: 28486109
pmcid: 5650691
doi: 10.1016/j.ccell.2017.04.003
Rébé, C. & Ghiringhelli, F. Interleukin-1β and cancer. Cancers 12, 1791 (2020).
pmcid: 7408158
doi: 10.3390/cancers12071791
Ridker, P. M. et al. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet 390, 1833–1842 (2017).
pubmed: 28855077
doi: 10.1016/S0140-6736(17)32247-X
Bruchard, M. et al. Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat. Med. 19, 57–64 (2013).
pubmed: 23202296
doi: 10.1038/nm.2999
Ghiringhelli, F. et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors. Nat. Med. 15, 1170–1178 (2009).
pubmed: 19767732
doi: 10.1038/nm.2028
Martínez-Reza, I. et al. Calcitriol inhibits the proliferation of triple-negative breast cancer cells through a mechanism involving the proinflammatory cytokines IL-1 β and TNF- α. J. Immunol. Res. 2019, 6384278 (2019).
pubmed: 31093512
pmcid: 6481021
doi: 10.1155/2019/6384278
Mitsunaga, S. et al. Serum levels of IL-6 and IL-1β can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer. Br. J. Cancer 108, 2063–2069 (2013).
pubmed: 23591198
pmcid: 3670479
doi: 10.1038/bjc.2013.174
Kim, J.-W. et al. Clinical implications of VEGF, TGF-β1, and IL-1β in patients with advanced non-small cell lung cancer. Cancer Res. Treat. 45, 325–333 (2013).
pubmed: 24454005
pmcid: 3893330
doi: 10.4143/crt.2013.45.4.325